Imaging and Biomarkers in Oncology

Susanne Kossatz 

Susanne Kossatz studied Biology at the Friedrich Schiller University Jena, from where she also obtained her PhD in the field of Molecular Imaging. She conducted her postdoctoral studies in the Thomas Reiner Lab at Memorial Sloan Kettering Cancer Center in New York. In April 2019, she joined the faculty of MRI-TUM as Rudolf Mößbauer Tenure Track Assistant Professor in the Department of Nuclear Medicine, where she heads the research group “Imaging and Biomarkers in Oncology”. Her research focuses on the development and clinical translation of molecular imaging tools for improved tumor detection, intraoperative delineation, treatment and monitoring. This includes radioactively and fluorescently labelled small molecules and peptides, their pharmacokinetic optimization, preclinical validation and translational studies for clinical use. A major research focus revolves around transforming inhibitors of the DNA repair enzyme PARP into powerful molecular tools for a variety of clinical applications for cancer diagnosis and therapy.

Research Focus

In our lab, we are a multidisciplinary team of biologists and chemists in close collaboration with clinicians, radiochemists, physicists and engineers working on a wide variety of research questions in the field of Molecular Imaging and Theranostics. Our goal is the development and clinical translation of molecular imaging and therapy tools for improved tumor detection, intraoperative delineation, patient stratification, treatment optimization and treatment monitoring.We are embedded in the research environment at TranslaTUM and the Nuclear Medicine Department, which allows us to utilize a diverse methodologic portfolio encompassing but not limited to organic synthesis, radiolabeling, HPLC, mass spectrometry, cell culture, in vitro characterization of new tracers, molecular biology e.g. protein expression analysis, confocal microscopy, animal model development, in vivo imaging of new tracers using PET, SPECT and optical imaging, autoradiography and histology. We are employing a growing number of targets for imaging and therapy (=theranostic) applications, including extracellular targets, such as integrins, PSMA, SSTR2 and intracellular targets, e.g. the DNA repair enzyme PARP1.

Key Awards

  • Alavi-Mandell Publication Award of the Society of Nuclear Medicine and Molecular Imaging (2019)
  • “30 under 35” early career professionals “to watch” in 2019 der Society of Nuclear Medicine and Molecular Imaging (SNMMI)(2019 
  • K99/R00 “Pathway to Independence” Award(2018)
  • Postdoctoral Research Fellowship from the Center of Molecular Imaging and Nanotechnology (CMINT) at Memorial Sloan Kettering Cancer Center(2015)
  • Chief Laboratory Research Fellow im Dept. of Radiology at Memorial Sloan Kettering Cancer Center(2015-2019)
  • Young Investigator Award from the  Center for Molecular Imaging Innovation and Translation (CMIIT) at the Society of Nuclear Medicine and Nuclear Imaging (SNMMI) annual meeting (2015)
  • Research Fellowship from the DFG(2014)
  • Young Investigator Award, 92nd German Radiology Conference (2011)

Selected Publications

  • Kossatz S, Pirovano G, De Souza França P, Strome A, Sunny S, Zanoni D, Mauguen A, Carney B, Brand C, Shah V, Ramanajinappa R, Hedne N, Birur P, Sihag S, Ghossein R, Gönen M, Strome M, Suresh A, Molena D, Kuriakose M, Patel S, Reiner T. PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers – first-in-human results. Preprint: bioRxiv. 2019 January; 663385. doi: 10.1101/663385.
  • Pirovano G, Jannetti S, Carter L, Sadique A, Kossatz S, Guru N, De Souza Franca P, Maeda M, Zeglis B, Lewis J, Humm J, Reiner T. Targeted brain tumor radiotherapy using an Auger emitter. Preprint: bioRxiv. 2019 January; 649764. doi: 10.1101/649764.
  • Gonzales J, Demetrio de Souza Franca P, Jiang Y, Pirovano G, Kossatz S, Guru N, Yarilin D, Agwa AJ, Schroeder CI, Patel SG, Ganly I, King GF, Reiner T. Fluorescence Imaging of Peripheral Nerves by a Nav1.7-Targeted Inhibitor Cystine Knot Peptide. Bioconjug Chem. 2019 PMID: 31647222.
  • Laird J, Lok BH, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier JT, Rudin CM. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. J Thorac Oncol. 2019 Oct;14(10):1743-1752. PMID: 31195178.
  • Mason C, Kossatz S, Carter L, Pirovano G, Brand C, Guru N, Pérez-Medina C, Lewis JS, Mulder W, Reiner T. A 89Zr-HDL PET tracer monitors response to a CSF1R inhibitor. J Nucl Med. 2019 PMID: 31420495.
  • Hernandez Vargas S, Kossatz S, Voss J, Ghosh SC, Tran Cao HS, Simien J, Reiner T, Dhingra S, Fisher WE, Azhdarinia A. Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Clin Cancer Res. 2019 Jul 15;25(14):4332-4342. PMID: 31015345.
  • Roberts S, Strome A, Choi C, Andreou C, Kossatz S, Brand C, Williams T, Bradbury M, Kircher MF, Reshetnyak YK, Grimm J, Lewis JS, Reiner T. Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. Sci Rep. 2019 Jun 12;9(1):8550. PMID: 31189972.
  • Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Eur Urol Oncol. 2019 Mar;2(2):166-173. PMID: 31017093.
  • Braza MS, van Leent MM, Lameijer M, Sanchez-Gaytan BL, Arts RJ, Pérez-Medina C, Brahmachary M, Fay F, Kluza E, Kossatz S, Dress RJ, Salem F, Rialdi A, Reiner T, Boros P, Strijkers GJ, Calcagno CC, Ginhoux F, Marazzi I, Lutgens E, Nicolaes GAF, Weber C, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WJM, Ochando J. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. Immunity, 2018, Nov 20;49(5):819-828.e6. PMID: 30413362.
  • Gonzales J, Kossatz S, Roberts S, Pirovano G, Brand C, Perez-Medina C, Donabedian P, De La Cruz M, Mulder W, Reiner, T. Nanoemulsion based delivery of fluorescent PARP inhibitors in mouse models of small cell lung cancer. Bioconjugate Chemistry, 2018, 29 (11), 3776-3782. PMID: 30354077.
  • Donabedian PL, Kossatz S, Engelback JA, Jannetti SA, Carney B, Young RJ, Weber WA, Garbow JR, Reiner T. Discriminating Radiation Injury from Recurrent Tumor with [18F]PARPi and Amino Acid PET in Mouse Models. European Journal of Nuclear Medicine and Molecular Imaging Research. EJNMMI research, 2018, 8(1), 59. PMID: 29974335.
  • Kossatz S*, Carney B, Farley C, Drain CM, Weber WA, Reiner T. Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib. Journal of Nuclear Medicine, 2018, 59 (8), 1316-1320. *corresponding author. PMID: 29572258.
  • Jannetti, SA, Carlucci G, Carney B, Kossatz S, Shenker L, Salinas B, Brand C, Sadique A, Donabedian PL, Cunanan KM, Gonen M, Ponomarev V, Zeglis BM, Souweidane MM, Lewis JS, Weber WA, Humm JL, Reiner T. PARP1-targeted radiotherapy in mouse models of glioblastoma. Journal of Nuclear Medicine, 2018, 59 (8), 1225-1233. PMID: 29572254.
  • Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty N, Weber WA, Rudin CM, Poirier JT, Reiner T. Target Engagement Imaging of PARP Inhibitors in Small Cell Lung Cancer. Nature Communications, 2018, Jan 12;9(1):176. PMID: 29330466.
  • Kossatz S, Weber WA, Reiner T. Commentary: Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Molecular Imaging, 2017, Jan-Dec; 16:1536012117723786. PMID: 28856922.
  • Büchel GE, Kossatz S, Sadique A, Rapta P, Zalibera M, Bucinsky L, Komorovsky S, Telser J, Eppinger J, Reiner T, Arion VB. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339. Dalton Transactions, 2017, Sep 12;46(35):11925-11941. PMID: 28850133.
  • Tang J, Salloum D, Carney B, Brand C, Kossatz S, Sadique A, Weber WA, Wendel HG, Reiner T. A Targeted PET Imaging Strategy to Differentiate Malignant from Inflamed Lymph Nodes in Diffuse Large B-Cell Lymphoma. Proceedings of the National Academy of Sciences, 2017, 201705013. PMID: 28827325.
  • Ghosh SC, Hernandez Vargas S, Rodriguez M, Kossatz S, Voss J, Carmon KS, Reiner T, Schonbrunn A, Azhdarinia A. Synthesis of a Fluorescently Labeled 68Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting. ACS Medicinal Chemistry Letters, 2017, Jun 6;8(7):720-725. PMID: 28740605.
  • Kossatz S, Carney B, Schweitzer ME, Carlucci G, Miloushev V, Maachani UB, Rajappa P, Keshari KR, Pisapia D, Weber WA, Souweidane MM, Reiner T. Biomarker based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Research, 2017, 77.8: 2112-2123. PMID: 28108511.
  • Kossatz S, Brand C, Gutiontov S, Liu JTC, Lee N, Gonen M, Weber WA, Reiner T. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Nature Scientific Reports, 2016, 21371. PMID: 26900125.
  • Kossatz S, Weber AW, Reiner T. Optical Imaging of PARP1 in response to radiation in Oral Squamous Cell Carcinoma. PloS one, 2016, 11.1: e0147752. PMID: 26808835.
  • Carney B, Carlucci G, Salinas B, Di Gialleonardo V, Kossatz S, Vansteene A, Longo VA, Bolaender A, Chiosis G, Keshari KR, Weber WA, Reiner T. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. Molecular Imaging and Biology, 2015, 18(3), 386-392. DOI: 10.1007/s11307-015-0904-y. PMID: 26493053.
  • Salinas B, Irwin CP, Kossatz S, Bolaender A, Chiosis G, Pillarsetty N, Weber WA, Reiner T.  Radioiodinated PARP1 tracers for glioblastoma imaging. EJNMMI research, 2015, 5(1), 123. PMID: 26337803.
  • Carlucci G, Carney B, Brand C, Kossatz S, Irwin C, Carlin SD, Keliher EJ, Weber WA, Reiner T. Dual Modality Optical/PET Imaging of PARP1 in Glioblastoma. Molecular Imaging and Biology, 2015, 17.6: 848-855. DOI: 10.1007/s11307-015-0858-0. PMID: 25895168.
  • Kossatz S, Grandke J, Couleaud P, Latorre A, Aires A, Crosbie-Staunton K, Ludwig R, Daehring H, Ettelt V, Lazaro-Carrillo A, Calero M, Sader M, Courty J, Volkov Y, Prina-Mello A, Villanueva A, Somoza A, Cortajareno AL, Miranda R, Hilger I. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Research, 2015, 17(1), 66. PMID: 25968050.
  • Kossatz S*, Ludwig R*, Dähring H, Ettelt V, Rimkus G, Marciello M, Salas G, Patel V, Teran FJ, Hilger I. High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area. Pharmaceutical Research, 2014, 31(12), 3274–88. *contributed equally PMID: 24890197.
  • Kossatz S, Mansi R, Béhé M, Czerney P, Hilger I. Influence of d-glutamine and d-glutamic Acid Sequences in Optical Peptide Probes Targeted against the Cholecystokinin-2/gastrin-Receptor on Binding Affinity, Specificity and Pharmacokinetic Properties. 2013, European Journal of Nuclear Medicine and Molecular Imaging Research (EJNMMI Research), 2013, Jan;3:75. PMID: 24238262.
  • Kossatz S, Béhé M, Mansi R, Czerney P, Kaiser WA, Hilger I. Multifactorial diagnostic imaging of CCK2R expressing tumors. Biomaterials, 2013, 34(21): 5172–5180. PMID: 23591397.
  • Franz M, Hilger I, Grün K, Kossatz S, Petersen I, Gummert J, Figulla HR, Kosmehl H, Neri D, Berndt A, Renner A. Selective imaging of chronic cardiac allograft rejection using a human antibody specific to the alternatively spliced ED-A domain of fibronectin. Journal of Heart and Lung Transplantation, 2013, June, 32 (6): 641-650. PMID: 23701854.

Laabs E, Béhé M, Kossatz S, Frank W, Kaiser WA, Hilger I. Optical imaging of CCK₂/gastrin receptor-positive tumors with a minigastrin near-infrared probe. Investigative Radiology, 2011, Mar;46(3):196–201. PMID: 21139504.

The Team